Immuneering Corporation

NasdaqGM:IMRX Stock Report

Market Cap: US$62.3m

Immuneering Management

Management criteria checks 3/4

Immuneering's CEO is Ben Zeskind, appointed in Feb 2008, has a tenure of 16.75 years. total yearly compensation is $1.92M, comprised of 30.9% salary and 69.1% bonuses, including company stock and options. directly owns 10.71% of the company’s shares, worth $6.67M. The average tenure of the management team and the board of directors is 3.2 years and 3.8 years respectively.

Key information

Ben Zeskind

Chief executive officer

US$1.9m

Total compensation

CEO salary percentage30.9%
CEO tenure16.8yrs
CEO ownership10.7%
Management average tenure3.2yrs
Board average tenure3.8yrs

Recent management updates

Recent updates

Companies Like Immuneering (NASDAQ:IMRX) Could Be Quite Risky

Aug 30
Companies Like Immuneering (NASDAQ:IMRX) Could Be Quite Risky

Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?

May 13
Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?

Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone

Mar 19

Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?

Jan 06
Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Rate

Aug 17
We're Not Very Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Rate

Immuneering wins FDA nod to study lead asset in solid tumors

Sep 30

Immuneering seeks FDA nod to conduct clinical trial for lead cancer candidate

Sep 02

Immuneering initiated a Buy by Chardan, PT set to $18

Jul 08

CEO Compensation Analysis

How has Ben Zeskind's remuneration changed compared to Immuneering's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$58m

Jun 30 2024n/an/a

-US$56m

Mar 31 2024n/an/a

-US$54m

Dec 31 2023US$2mUS$593k

-US$53m

Sep 30 2023n/an/a

-US$52m

Jun 30 2023n/an/a

-US$52m

Mar 31 2023n/an/a

-US$51m

Dec 31 2022US$2mUS$570k

-US$51m

Sep 30 2022n/an/a

-US$48m

Jun 30 2022n/an/a

-US$44m

Mar 31 2022n/an/a

-US$40m

Dec 31 2021US$2mUS$400k

-US$34m

Sep 30 2021n/an/a

-US$29m

Jun 30 2021n/an/a

-US$24m

Mar 31 2021n/an/a

-US$20m

Dec 31 2020US$806kUS$293k

-US$17m

Compensation vs Market: Ben's total compensation ($USD1.92M) is above average for companies of similar size in the US market ($USD649.07K).

Compensation vs Earnings: Ben's compensation has been consistent with company performance over the past year.

CEO

Ben Zeskind (41 yo)

16.8yrs

Tenure

US$1,918,201

Compensation

Dr. Benjamin J. Zeskind, also known as Ben, Ph D., MBA serves as the Co-Founder, President, Chief Executive Officer and Director of Immuneering Corporation since February 2008 and served as its Secretary....

Leadership Team

NamePositionTenureCompensationOwnership
Benjamin Zeskind
Co-Founder16.8yrsUS$1.92m10.71%
$ 6.7m
Robert Carpenter
Co-Founder & Chair Emeritus16.8yrsUS$202.74k3.87%
$ 2.4m
Brett Hall
Chief Scientific Officer5yrsUS$1.40m1.17%
$ 726.4k
Harold Brakewood
Chief Business Officer1.7yrsUS$1.57m0.013%
$ 8.2k
Mallory Morales
Principal Financial & Accounting Officer2.3yrsno data0.043%
$ 26.7k
Paula George
Director of Accounting & Operations and Assistant Corporate Controller3.2yrsno datano data
Michael Bookman
Chief Legal Officer & Secretary3.3yrsno data0.013%
$ 8.1k
Leah Neufeld
Chief People Officer2.1yrsno data0.034%
$ 21.1k
Peter King
Head of Discovery & VPno datano datano data
Praveen Nair
Head of Translational Pharmacology & VP2.7yrsno datano data
Stephen Sebastian
Executive Director & Corporate Controller3.2yrsno datano data

3.2yrs

Average Tenure

51yo

Average Age

Experienced Management: IMRX's management team is considered experienced (3.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Benjamin Zeskind
Co-Founder16.8yrsUS$1.92m10.71%
$ 6.7m
Robert Carpenter
Co-Founder & Chair Emeritus15.5yrsUS$202.74k3.87%
$ 2.4m
Laurie Keating
Independent Director3.7yrsUS$179.88k0.047%
$ 29.4k
Douglas Lauffenburger
Co-Chairman of Scientific Advisory Boardno datano datano data
Peter Feinberg
Director3.8yrsUS$165.67k3.7%
$ 2.3m
Ann Berman
Independent Chair3.3yrsUS$181.38k0.23%
$ 141.7k
Diana Hausman
Independent Director2.8yrsUS$175.38k0%
$ 0
Max Artyomov
Co-Chairman of Scientific Advisory Boardno datano datano data
Bijan Nejadnik
Member of Scientific Advisory Boardno datano datano data
Tanios Bekaii-Saab
Member of Scientific Advisory Boardno datano datano data
Daniel Ahn
Member of Scientific Advisory Boardno datano datano data
Denis Guttridge
Member of Scientific Advisory Boardno datano datano data

3.8yrs

Average Tenure

63yo

Average Age

Experienced Board: IMRX's board of directors are considered experienced (3.8 years average tenure).